Literature DB >> 16632315

Neoplastic meningitis.

Beate Gleissner1, Marc Charles Chamberlain.   

Abstract

Neoplastic meningitis is a complication of the CNS that occurs in 3-5% of patients with cancer and is characterised by multifocal neurological signs and symptoms. Diagnosis is problematic because the disease is commonly the result of pleomorphic manifestations of neoplastic meningitis and co-occurrence of disease at other sites. Useful tests to establish diagnosis and guide treatment include MRI of the brain and spine, cerebrospinal fluid (CSF) cytology, and radioisotope CSF flow studies. Assessment of the extent of disease of the CNS is of value because large-volume subarachnoid disease or CSF flow obstruction is prognostically significant. Radiotherapy is an established and beneficial treatment for patients with neoplastic meningitis with large tumour volume including parenchymal brain metastasis, sites of symptomatic disease, or CSF flow block. Because neoplastic meningitis affects the entire neuraxis, chemotherapy treatment can include intra-CSF fluid (either intraventricular or intralumbar) or systemic therapy. Most patients (>70%) with neoplastic meningitis have progressive systemic disease and consequently treatment is palliative and tumour response is of restricted durability. Furthermore, as there is no compelling evidence of a survival advantage with aggressive multimodal treatment, future trials need be done to determine the effect of treatment on quality of life and control of neurological symptoms.

Entities:  

Mesh:

Year:  2006        PMID: 16632315     DOI: 10.1016/S1474-4422(06)70443-4

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  75 in total

Review 1.  State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer.

Authors:  Alessandro Inno; Vincenzo Di Noia; Ettore D'Argento; Alessandra Modena; Stefania Gori
Journal:  Transl Lung Cancer Res       Date:  2016-12

2.  Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.

Authors:  Youngjoo Lee; Ji-Youn Han; Heung Tae Kim; Tak Yun; Geon Kook Lee; Hyae Young Kim; Jin Soo Lee
Journal:  J Neurooncol       Date:  2013-07-06       Impact factor: 4.130

Review 3.  Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.

Authors:  Grainne M O'Kane; Natasha B Leighl
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

Review 4.  Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials.

Authors:  Marc Chamberlain; Riccardo Soffietti; Jeffrey Raizer; Roberta Rudà; Dieta Brandsma; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Larry Junck; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle
Journal:  Neuro Oncol       Date:  2014-05-27       Impact factor: 12.300

5.  Contribution of CSF cytology in the diagnostic work-up of breast cancer patients with neurological symptoms: a retrospective analysis over two decades.

Authors:  C A P Wauters; J Poelen; I Mulder; D Venderink; L J A Strobbe; P Wesseling
Journal:  J Neurooncol       Date:  2012-01-04       Impact factor: 4.130

6.  Contrast-enhanced modified 3D T1-weighted TSE black-blood imaging can improve detection of infectious and neoplastic meningitis.

Authors:  Nora Navina Sommer; Romina Pons Lucas; Eva Coppenrath; Hendrik Kooijman; Franziska Galiè; Nina Hesse; Wieland H Sommer; Karla M Treitl; Tobias Saam; Matthias F Froelich
Journal:  Eur Radiol       Date:  2019-11-05       Impact factor: 5.315

7.  Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment.

Authors:  Ticiana Leal; Julie E Chang; Minesh Mehta; H Ian Robins
Journal:  Curr Cancer Ther Rev       Date:  2011-11

8.  Subacute onset of deafness and vertigo in a patient with leptomeningeal metastasis from ovarian cancer.

Authors:  Roberta Vitaliani; Marco Spinazzi; Anna Rosa Del Mistro; Renzo Manara; Bruno Tavolato; Domenico Marco Bonifati
Journal:  Neurol Sci       Date:  2009-01-16       Impact factor: 3.307

9.  Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience.

Authors:  P Gaviani; E Corsini; A Salmaggi; E Lamperti; A Botturi; A Erbetta; I Milanesi; F Legnani; B Pollo; A Silvani
Journal:  Neurol Sci       Date:  2013-03-24       Impact factor: 3.307

10.  Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?

Authors:  Lijuan Deng; Yuqin Song; Jun Zhu; Wen Zheng; Xiaopei Wang; Yan Xie; Ningjing Lin; Meifeng Tu; Lingyan Ping; Zhitao Ying; Weiping Liu; Chen Zhang
Journal:  Int J Hematol       Date:  2013-12       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.